|
Age (years)
|
54.63 ± 8.98
|
57.10 ± 14.13
|
0.419
|
|
Male, n (%)
|
26 (86.7%)
|
26 (83.9%)
|
1.000
|
|
Hypertension, n (%)
|
5 (16.7%)
|
11 (35.5%)
|
0.095
|
|
Diabetes mellitus, n (%)
|
6 (20%)
|
7 (22.6%)
|
0.806
|
|
Smoking, n (%)
|
17 (56.7%)
|
12 (38.7%)
|
0.160
|
|
Family history of CAD, n (%)
|
3 (10%)
|
3 (9.7%)
|
1.000
|
|
BMI (kg/m2)
|
25.4 ± 4.17
|
25.10 ± 3.04
|
0.753
|
|
BSA (m2)
|
1.74 ± 0.13
|
1.74 ± 0.12
|
0.891
|
|
Symptom to thrombolysis time (hours)
|
4.77 ± 1.60
|
4.67 ± 1.47
|
0.809
|
|
Thrombolysis to PCI time (hours)
|
16.03 ± 1.37
|
15.71 ± 1.40
|
0.377
|
|
Hemoglobin (g/dL)
|
13.19 ± 1.85
|
13.31 ± 2.06
|
0.822
|
|
Creatinine (mg/dL)
|
1.1 ± 0.17
|
1.07 ± 0.18
|
0.485
|
|
Total cholesterol (mg/dL)
|
152.1 ± 52.85
|
139 ± 30.16
|
0.262
|
|
Triglycerides (mg/dL)
|
134.1 ± 47.18
|
119.2 ± 40.82
|
0.208
|
|
LDL-cholesterol (mg/dL)
|
100.8 ± 54.47
|
86.6 ± 33.42
|
0.247
|
|
HDL-cholesterol (mg/dL)
|
38.18 ± 9.05
|
38.84 ± 11.74
|
0.814
|
|
CK-MB (IU/l)
|
40 (36.25–53)
|
37 (31 − 97.75)
|
0.852
|
|
Ejection fraction, (%)
|
43.40 ± 4.28
|
40.25 ± 6.34
|
0.027
|
|
Thrombolysis, n (%)
|
0.656
|
|
Streptokinase
|
24 (80%)
|
22 (71%)
|
|
Reteplase
|
6 (20%)
|
8 (25.8%)
|
|
Tenecteplase
|
0 (0%)
|
1 (3.2%)
|
|
GP IIb-IIIa inhibitor use, n (%)
|
11 (36.7%)
|
10 (32.3%)
|
0.717
|
|
Medications at admission (%)
|
|
Antiplatelets (%)
|
2 (6.6%)
|
3 (9.6%)
|
1.000
|
|
Statins (%)
|
3 (10%)
|
4 (12.9%)
|
1.000
|
|
Beta blockers (%)
|
2 (6.6%)
|
5 (16.1%)
|
0.425
|
|
ACE I/ARBs (%)
|
4 (13.3%)
|
5 (16.1%)
|
1.000
|
|
OHAs (%)
|
3 (10%)
|
5 (16.1%)
|
0.707
|
|
Insulin (%)
|
2 (6.6%)
|
1 (3.2%)
|
0.612
|
